Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

AtaiBeckley Inc. - Common Stock (NQ:ATAI)

4.900 +0.870 (+21.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AtaiBeckley Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
News headline image
Why AtaiBeckley Stock Surged Today ↗
President Trump wants to fast-track psychedelic research. 
Via The Motley Fool
Topics Government
News headline image
Small-Cap Medical Stocks: ATAI, CMPS, NDRA, PBM in Focus as U.S. Policy Accelerates Psychedelic Research
Via AB Newswire
News headline image
This 4/20, Wall Street Is Betting on More Than Marijuana ↗
Via MarketBeat
News headline image
AtaiBeckley Stock Skyrockets After Cantor Fitzgerald's Overweight Rating ↗
AtaiBeckley (NASDAQ:ATAI) shares are surging Monday as psychedelic biotechs rally on President Trump's executive order to fast-track reviews. 
Via Benzinga
Topics Government
What's going on in today's session ↗
Via Chartmill
News headline image
Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soar ↗
Trump is easing approval for psychedelic treatments for mental disorders. 
Via The Motley Fool
Topics Government
These stocks are gapping in today's session ↗
Via Chartmill
Top movers in Monday's pre-market session ↗
Via Chartmill
News headline image
The 15-Minute Breakthrough: A Deep Dive into GH Research (GHRS) and the Future of Rapid-Acting Psychedelics
Today’s Date: March 26, 2026 Introduction As the global mental health crisis reaches unprecedented levels, the pharmaceutical industry has been forced to look beyond traditional SSRIs toward more... 
Via Finterra
Topics Cannabis Initial Public Offering Intellectual Property
News headline image
AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst
From AtaiBeckley Inc.
Via GlobeNewswire
News headline image
BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation
From AtaiBeckley Inc.
Via GlobeNewswire
News headline image
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day
From AtaiBeckley Inc.
Via GlobeNewswire
News headline image
ENDRA Life Sciences (NASDAQ: NDRA): The GLP-1 Healthcare Boom Offering Tremendous Opportunity Watch HIMS, ANTX, ATAI, PURR Now!
Via AB Newswire
News headline image
AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update
From AtaiBeckley Inc.
Via GlobeNewswire
News headline image
AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley To Host Virtual Investor Day on March 6, 2026
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Appoints Michael Faerm as Chief Financial Officer
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley To Participate in Upcoming Investor Conferences
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 ↗
Via MarketBeat
News headline image
AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
GH Research Stock Grabs Retail Spotlight Ahead Of FDA Update On Depression Treatment ↗
GH001 showed symptom improvement, high remission rates, and sustained benefits in a Phase 2b trial for treatment-resistant depression. 
Via Stocktwits
News headline image
AtaiBeckley Completes Redomiciliation to the United States
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
MarketBeat’s Top 5 Rated Small-Cap Stocks ↗
Via MarketBeat
News headline image
Optimism Flows From Pot To Psychedelics: Atai Beckley, Supernus Stocks Rise After Analyst Flags Positive Tailwinds From Trump’s Marijuana Order ↗
Jefferies sees restrictions around non-recreational psychedelics eventually loosen up. 
Via Stocktwits
Topics Cannabis ETFs Government
News headline image
AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London
From AtaiBeckley N.V.
Via GlobeNewswire
News headline image
AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
AtaiBeckley solidifies position as a global leader in transformative mental health therapies with a short psychedelic duration 
From AtaiBeckley N.V.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.